United States

Choose your country or region:

DIGITAL NEWSROOM

Posts in: Investor Relations

November 01, 2023

Exact Sciences Announces Third-Quarter 2023 Results
September 12, 2023

Agilent Technologies and Exact Sciences Agree to Terms of Sale for Resolution Bioscience
August 01, 2023

Exact Sciences Announces Second-Quarter 2023 Results
June 21, 2023

Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
June 20, 2023

Next Generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent specificity, Raising the Bar in Non-invasive Screening
May 09, 2023

Exact Sciences Announces First Quarter 2023 Results
February 21, 2023

Exact Sciences Announces Fourth Quarter 2022 Results
January 08, 2023

Exact Sciences Announces Preliminary Fourth Quarter 2022 Results
November 03, 2022

Exact Sciences Announces Third Quarter 2022 Results Reports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
October 24, 2022

Exact Sciences Expands Leadership in Colorectal Cancer Screening with New Data Presented at the American College of Gastroenterology 2022 Annual Meeting
April 28, 2017

Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests
October 03, 2016

What Cologuard's Inclusion in HEDIS Means